Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer response to questions on M&A -> add value to company

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 20, 2022 12:26pm

161 Views

Post# 35036629

RE:RE:RE:Pfizer response to questions on M&A -> add value to company

In oncology, most of the company's Phase 3 programs are in testing potential label expansions for the company's already approved "follow-on" drugs, and not for innovative unapproved drugs, which places ONCY's pelareorep as a critical M&A target for Pfizer. As for unapproved candidates in that category, Pfizer only has sasanlimab in non-muscle-invasive bladder cancer and elranatamab in multiple myeloma in late-stage testing.

https://www.fiercepharma.com/pharma/something-prove-pfizer-launch-10-new-drugs-during-next-years-pivotal-year-says-ceo-albert

<< Previous

Bullboard Posts

Next >>

Junior helium miner will explore record discovery in Q4